Results 181 to 190 of about 19,152,238 (244)

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy

British Journal of Haematology, EarlyView.
Isacco Ferrarini, Daniela Estefania Banegas, Andrea Bernardelli, Alessia Moioli, Francesca Maria Quaglia, Ester Lovato, Anna Maria Frustaci, Massimiliano Postorino, Davide Facchinelli, Monica Tani, Francesca Cibien, Chandrakala Toldo, Elisa Lucchini, Roberto Marasca, Marzia Varettoni, Chiara Rusconi, Lucia Farina, Andrea Visentin, Riccardo Moia, Carlo Visco   +19 more
wiley   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Dysregulated TIE‐2 expression in Alzheimer's disease: Further considerations on regional specificity and shedding evidence

Brain Pathology, EarlyView.
Shi‐qi Zhang, Meichen Liu
wiley   +1 more source

Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights

British Journal of Pharmacology, EarlyView.
Cardiac metabolic remodelling in anthracycline‐induced cardiomyopathy and metabolically oriented cardioprotective strategies. Schematic representation of substrate utilization, mitochondrial bioenergetic function and metabolic flexibility in the healthy heart, in anthracycline‐induced cardiomyopathy and under potential cardioprotective interventions ...
Giulia Guerra, Francesco Niro, Marco Mergiotti, Giovanni Gavatorta, Emilio Hirsch, Alessandra Ghigo   +5 more
wiley   +1 more source

Commentary beyond the ATP site: Cryo-EM views of allosteric PI3K<i>α</i> inhibition. [PDF]

Acta Pharm Sin B
Paetzel BG, Burke JE.
europepmc   +1 more source

Evidence That the Protein Phosphatase Activity of PTEN Contributes to Embryonic Development and Tumor Suppression

Cancer Science, EarlyView.
Mice expressing only mutant PTEN Y138L, a protein which shows normal suppression of cellular AKT yet lacks protein phosphatase activity, die in utero, and heterozygous mice display a range of tumors. This indicates both the lipid and protein phosphatase activities of PTEN work together for normal tumor suppression and embryonic development.
Priyanka Tibarewal, Laura Spinelli, Nisha Kriplani, Helen Wise, Nadege Poncet, Giulia Marzano, Karen E. Anderson, Katarzyna M. Grzes, Zofia Varyova, Mahreen Adil, C. Peter Downes, Phillip T. Hawkins, Len R. Stephens, Kate G. Storey, Doreen A. Cantrell, Bart Vanhaesebroeck, Nicholas R. Leslie   +16 more
wiley   +1 more source

Understanding the distinct role of PI3K(p110<i>α</i>) in cancer and the heart to prevent chemotherapy-induced cardiotoxicity: mechanisms and therapeutic opportunities. [PDF]

Front Cardiovasc Med
Belkin TG, Tham YK, Edgley AJ, McMullen JR.   +3 more
europepmc   +1 more source

Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy

Cancer Science, EarlyView.
This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang, Changyi Fan, Shiheng Chen, Tianyue Lu, Yuanyuan Li, Feng Du, Shanshan Wang   +6 more
wiley   +1 more source

A review of PI3K/AKT/mTOR inhibitors from traditional Chinese medicine: potential and perspective for activated phosphoinositide 3-kinase δ syndrome. [PDF]

Orphanet J Rare Dis
Xie Y, Nie L, Bai L, Zhao X.
europepmc   +1 more source

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

Cancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source